That's no good about a patient passing. 21 months is below the average survival of 27 months?
I noticed the comment from CEO was trial on track to commence CY2024...I hope this is not the start of goal posts moving (from Q2 2024). Please let's not go back to the PAA of old.
Overall neutral summary but I think the market will punish it.
1. Patient death somewhat early compared to overall average
2. Trial start now 'this year'rather than a specific point
3. Funding...we all know its likely dilution and at this depressed price after CEO resignation
That's no good about a patient passing. 21 months is below the...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.015(7.32%) |
Mkt cap ! $87.1M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 21.0¢ | $134.7K | 629.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24563 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 64222 | 3 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.5¢ |
Change
0.015 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 21.0¢ | 22.0¢ | 21.0¢ | 340156 | ||
| Last updated 15.57pm 07/06/2024 ? | |||||
| PAA (ASX) Chart |